Literature DB >> 15121049

Mutations in CD46, a complement regulatory protein, predispose to atypical HUS.

Timothy H J Goodship1, M Kathryn Liszewski, Elizabeth J Kemp, Anna Richards, John P Atkinson.   

Abstract

Membrane cofactor protein (MCP, CD46) is a widely expressed transmembrane complement regulator. As does the soluble regulator factor H, it inhibits complement activation by inactivating the C3b that is deposited on target membranes. Factor H mutations have been described in 15-30% of patients with atypical haemolytic uraemic syndrome (HUS). Recent studies have identified mutations in the MCP gene in four families. In one, a heterozygous deletion resulted in the intracellular retention of the mutant protein. In another, a different heterozygous deletion led to a premature stop codon and the loss of the C-terminus. In the other two, a substitution (S206P) resulted in cell-surface expression but inefficient inactivation of surface-bound C3b. These findings provide further evidence that complement dysregulation predisposes to the development of HUS.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15121049     DOI: 10.1016/j.molmed.2004.03.006

Source DB:  PubMed          Journal:  Trends Mol Med        ISSN: 1471-4914            Impact factor:   11.951


  18 in total

1.  Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome.

Authors:  Philipp A Lang; Ortraud Beringer; Jan P Nicolay; Oliver Amon; Daniela S Kempe; Tobias Hermle; Philipp Attanasio; Ahmad Akel; Richard Schäfer; Björn Friedrich; Teut Risler; Matthias Baur; Christoph J Olbricht; Lothar Bernd Zimmerhackl; Peter F Zipfel; Thomas Wieder; Florian Lang
Journal:  J Mol Med (Berl)       Date:  2006-04-19       Impact factor: 4.599

2.  Anti-mouse properdin TSR 5/6 monoclonal antibodies block complement alternative pathway-dependent pathogenesis.

Authors:  Paula Bertram; Antonina M Akk; Hui-fang Zhou; Lynne M Mitchell; Christine T N Pham; Dennis E Hourcade
Journal:  Monoclon Antib Immunodiagn Immunother       Date:  2015-02

3.  Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome: emerging insights for vascular integrity.

Authors:  Peter Densen
Journal:  Curr Infect Dis Rep       Date:  2005-09       Impact factor: 3.725

4.  A case of atypical hemolytic uremic syndrome with a transient decrease in complement factor H.

Authors:  Hyewon Hahn; Eun Young Um; Young Seo Park; Hae Il Cheong
Journal:  Pediatr Nephrol       Date:  2005-12-17       Impact factor: 3.714

Review 5.  Pathogenic role of antiphospholipid antibodies.

Authors:  J E Salmon; P G de Groot
Journal:  Lupus       Date:  2008-05       Impact factor: 2.911

6.  Why Do We Need ADAMTS13?

Authors:  Han-Mou Tsai
Journal:  Nihon Kessen Shiketsu Gakkai shi       Date:  2005

7.  Access to the complement factor B scissile bond is facilitated by association of factor B with C3b protein.

Authors:  Dennis E Hourcade; Lynne M Mitchell
Journal:  J Biol Chem       Date:  2011-08-23       Impact factor: 5.157

8.  Hemolytic uremic syndrome after renal transplantation.

Authors:  G V Vergoulas
Journal:  Hippokratia       Date:  2006-07       Impact factor: 0.471

9.  Modeling how CD46 deficiency predisposes to atypical hemolytic uremic syndrome.

Authors:  M Kathryn Liszewski; Marilyn K Leung; Barbara Schraml; Timothy H J Goodship; John P Atkinson
Journal:  Mol Immunol       Date:  2006-10-05       Impact factor: 4.407

Review 10.  Translational mini-review series on complement factor H: therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis.

Authors:  M Noris; G Remuzzi
Journal:  Clin Exp Immunol       Date:  2007-12-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.